Combined analysis of miR-200 family and its significance for breast cancer

Abstract While the molecular functions of miR-200 family have been deeply investigated, a role for these miRNAs as breast cancer biomarkers remains largely unexplored. In the attempt to clarify this, we profiled the miR-200 family members expression in a large cohort of breast cancer cases with a lo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Andrea Fontana, Raffaela Barbano, Elisa Dama, Barbara Pasculli, Michelina Rendina, Maria Grazia Morritti, Valentina Melocchi, Marina Castelvetere, Vanna Maria Valori, Sara Ravaioli, Sara Bravaccini, Luigi Ciuffreda, Paolo Graziano, Evaristo Maiello, Massimiliano Copetti, Vito Michele Fazio, Manel Esteller, Fabrizio Bianchi, Paola Parrella
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/7f115660f6094fd1a43b8c2f4d61692a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract While the molecular functions of miR-200 family have been deeply investigated, a role for these miRNAs as breast cancer biomarkers remains largely unexplored. In the attempt to clarify this, we profiled the miR-200 family members expression in a large cohort of breast cancer cases with a long follow-up (H-CSS cohort) and in TCGA-BRCA cohort. Overall, miR-200 family was found upregulated in breast tumors with respect to normal breast tissues while downregulated in more aggressive breast cancer molecular subtypes (i.e. Luminal B, HER2 and triple negative), consistently with their function as repressors of the epithelial-to-mesenchymal transition (EMT). In particular miR-141-3p was found differentially expressed in breast cancer molecular subtypes in both H-CSS and TCGA-BRCA cohorts, and the combined analysis of all miR-200 family members demonstrated a slight predictive accuracy on H-CSS cancer specific survival at 12 years (survival c-statistic: 0.646; 95%CI 0.538–0.754).